Post by tomsylver on Jun 13, 2018 13:36:23 GMT
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
Dear Shareholder:
We are pleased to invite you to attend the 2018 Annual Meeting of the shareholders of Cocrystal Pharma, Inc., which will be held
at 2:00 p.m. EST on August 6, 2018 at 4400 Biscayne Boulevard, Suite 1500, Miami, Florida 33137, for the following purposes:
1. To elect six members to our Board of Directors;
2. To approve an amendment to Cocrystal’s Certificate of Incorporation to reduce the number of shares of common stock
Cocrystal is authorized to issue from 800,000,000 to 100,000,000;
3. To approve, on an advisory basis, Cocrystal’s Named Executive Officer compensation;
4. To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; and
Cocrystal’s Board of Directors has fixed the close of business on June 11, 2018 as the record date for a determination of shareholders entitled to notice of, and to vote at, this Annual Meeting or any adjournment thereof.
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to Be Held on August 6, 2018:
We mailed a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access our Proxy Statement and our 2017 Annual Report on Form 10-K on or about June 25, 2018.
This Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 are available at: www.equitystock.com free of charge
Dear Shareholder:
We are pleased to invite you to attend the 2018 Annual Meeting of the shareholders of Cocrystal Pharma, Inc., which will be held
at 2:00 p.m. EST on August 6, 2018 at 4400 Biscayne Boulevard, Suite 1500, Miami, Florida 33137, for the following purposes:
1. To elect six members to our Board of Directors;
2. To approve an amendment to Cocrystal’s Certificate of Incorporation to reduce the number of shares of common stock
Cocrystal is authorized to issue from 800,000,000 to 100,000,000;
3. To approve, on an advisory basis, Cocrystal’s Named Executive Officer compensation;
4. To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; and
5. To transact such other matters as may properly come before the Annual Meeting.
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to Be Held on August 6, 2018:
We mailed a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access our Proxy Statement and our 2017 Annual Report on Form 10-K on or about June 25, 2018.
This Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 are available at: www.equitystock.com free of charge
